ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Latest NewsMORE >>

Based on phase III results from the PROSELICA trial, the FDA has approved the combination of cabazitaxel at a dose of 20 mg/m2 every 3 weeks and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.